SG11202006334XA - Edb targeting il-12 compositions - Google Patents
Edb targeting il-12 compositionsInfo
- Publication number
- SG11202006334XA SG11202006334XA SG11202006334XA SG11202006334XA SG11202006334XA SG 11202006334X A SG11202006334X A SG 11202006334XA SG 11202006334X A SG11202006334X A SG 11202006334XA SG 11202006334X A SG11202006334X A SG 11202006334XA SG 11202006334X A SG11202006334X A SG 11202006334XA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- edb
- targeting
- edb targeting
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18156141 | 2018-02-09 | ||
EP18179313 | 2018-06-22 | ||
PCT/EP2019/053136 WO2019154986A1 (en) | 2018-02-09 | 2019-02-08 | Edb targeting il-12 compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202006334XA true SG11202006334XA (en) | 2020-08-28 |
Family
ID=65268973
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202006334XA SG11202006334XA (en) | 2018-02-09 | 2019-02-08 | Edb targeting il-12 compositions |
Country Status (22)
Country | Link |
---|---|
US (1) | US20200397915A1 (ja) |
EP (1) | EP3749372A1 (ja) |
JP (2) | JP7279054B2 (ja) |
KR (2) | KR102259085B1 (ja) |
CN (1) | CN111683687A (ja) |
AU (2) | AU2019219201B2 (ja) |
BR (1) | BR112020012888A2 (ja) |
CA (1) | CA3087488C (ja) |
CL (1) | CL2020002052A1 (ja) |
CO (1) | CO2020009737A2 (ja) |
CR (1) | CR20200342A (ja) |
CU (1) | CU20200054A7 (ja) |
EC (1) | ECSP20047171A (ja) |
IL (1) | IL275713A (ja) |
JO (1) | JOP20200193A1 (ja) |
MX (1) | MX2020008231A (ja) |
PE (1) | PE20210122A1 (ja) |
PH (1) | PH12020551230A1 (ja) |
RU (2) | RU2021130306A (ja) |
SG (1) | SG11202006334XA (ja) |
UY (1) | UY38074A (ja) |
WO (1) | WO2019154986A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102524247B1 (ko) * | 2018-12-21 | 2023-04-21 | 가톨릭대학교 산학협력단 | p40-EBI3의 복합체 및 이의 용도 |
EP4028413A1 (en) | 2019-09-10 | 2022-07-20 | Obsidian Therapeutics, Inc. | Ca2-il15 fusion proteins for tunable regulation |
WO2021209452A1 (en) | 2020-04-14 | 2021-10-21 | Philogen S.P.A. | Dosage units and regimen, uses, methods or formulations of compositions comprising a recombinant protein comprising interleukin-12 and an antibody binding the extra-domain b of fibronectin |
KR102649794B1 (ko) * | 2020-10-19 | 2024-03-22 | 고려대학교 산학협력단 | 암 및/또는 뇌질환 바이오마커인 엑스트라-도메인 b 파이브로넥틴 및 이를 이용한 진단 방법 |
WO2023131611A1 (en) * | 2022-01-04 | 2023-07-13 | Philogen S.P.A. | Combination of an immunocytokine comprising il-12 and a kinase inhibitor |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
US5994104A (en) * | 1996-11-08 | 1999-11-30 | Royal Free Hospital School Of Medicine | Interleukin-12 fusion protein |
JP2003524018A (ja) | 2000-02-24 | 2003-08-12 | アイトゲネーシシェ テクニシェ ホッホシューレ チューリッヒ | フィブロネクチンのed‐bドメインに特異的な抗体、前記抗体を含む複合体、および血管形成を検出および治療するためのその使用 |
ATE333900T1 (de) * | 2000-02-24 | 2006-08-15 | Philogen Spa | Zusamensetzungen und verfahren zur behandlung von angiogenese in pathologischen schädigungen |
PT1483297E (pt) | 2002-03-11 | 2010-03-29 | Philogen Spa | Anticorpos derivados de anti-ed-b l19 e direccionamento para a vasculatura tumoral |
MX2007013875A (es) | 2005-05-11 | 2008-01-28 | Philogen Spa | Proteinas de fusion del anticuerpo l19 contra fibronectina ed-b e interlucina 12. |
SG178443A1 (en) * | 2009-08-17 | 2012-04-27 | Roche Glycart Ag | Targeted immunoconjugates |
EP3834847A1 (en) * | 2011-07-27 | 2021-06-16 | Philogen S.p.A. | Il-12 immunoconjugate |
WO2017062953A1 (en) * | 2015-10-10 | 2017-04-13 | Intrexon Corporation | Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12 |
AU2018226215B2 (en) * | 2017-02-24 | 2019-11-21 | Philogen S.P.A. | Immunoconjugates with optimized linkers and orientation |
-
2019
- 2019-02-07 UY UY38074A patent/UY38074A/es not_active Application Discontinuation
- 2019-02-08 CR CR20200342A patent/CR20200342A/es unknown
- 2019-02-08 CU CU2020000054A patent/CU20200054A7/es unknown
- 2019-02-08 KR KR1020207025138A patent/KR102259085B1/ko active IP Right Grant
- 2019-02-08 BR BR112020012888-0A patent/BR112020012888A2/pt unknown
- 2019-02-08 SG SG11202006334XA patent/SG11202006334XA/en unknown
- 2019-02-08 JO JOP/2020/0193A patent/JOP20200193A1/ar unknown
- 2019-02-08 WO PCT/EP2019/053136 patent/WO2019154986A1/en unknown
- 2019-02-08 RU RU2021130306A patent/RU2021130306A/ru unknown
- 2019-02-08 AU AU2019219201A patent/AU2019219201B2/en active Active
- 2019-02-08 RU RU2020127719A patent/RU2758143C1/ru active
- 2019-02-08 CA CA3087488A patent/CA3087488C/en active Active
- 2019-02-08 EP EP19702649.5A patent/EP3749372A1/en active Pending
- 2019-02-08 MX MX2020008231A patent/MX2020008231A/es unknown
- 2019-02-08 KR KR1020217015607A patent/KR102488801B1/ko active IP Right Grant
- 2019-02-08 CN CN201980012247.6A patent/CN111683687A/zh active Pending
- 2019-02-08 PE PE2020001190A patent/PE20210122A1/es unknown
- 2019-02-08 US US16/968,445 patent/US20200397915A1/en active Pending
- 2019-02-08 JP JP2020542822A patent/JP7279054B2/ja active Active
-
2020
- 2020-06-28 IL IL275713A patent/IL275713A/en unknown
- 2020-08-06 CO CONC2020/0009737A patent/CO2020009737A2/es unknown
- 2020-08-06 EC ECSENADI202047171A patent/ECSP20047171A/es unknown
- 2020-08-07 CL CL2020002052A patent/CL2020002052A1/es unknown
- 2020-08-07 PH PH12020551230A patent/PH12020551230A1/en unknown
-
2021
- 2021-06-16 AU AU2021203986A patent/AU2021203986A1/en active Pending
-
2023
- 2023-05-10 JP JP2023077703A patent/JP2023113648A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CO2020009737A2 (es) | 2020-08-21 |
PH12020551230A1 (en) | 2021-05-17 |
PE20210122A1 (es) | 2021-01-19 |
US20200397915A1 (en) | 2020-12-24 |
KR20210063467A (ko) | 2021-06-01 |
RU2021130306A (ru) | 2021-11-10 |
AU2021203986A1 (en) | 2021-07-08 |
KR102259085B1 (ko) | 2021-06-03 |
CU20200054A7 (es) | 2021-05-12 |
CR20200342A (es) | 2020-10-19 |
JOP20200193A1 (ar) | 2020-08-06 |
ECSP20047171A (es) | 2020-09-30 |
KR20200109380A (ko) | 2020-09-22 |
IL275713A (en) | 2020-08-31 |
JP7279054B2 (ja) | 2023-05-22 |
CA3087488A1 (en) | 2019-08-15 |
CA3087488C (en) | 2021-11-02 |
CN111683687A (zh) | 2020-09-18 |
TW201934136A (zh) | 2019-09-01 |
JP2023113648A (ja) | 2023-08-16 |
KR102488801B1 (ko) | 2023-01-13 |
WO2019154986A1 (en) | 2019-08-15 |
RU2758143C1 (ru) | 2021-10-26 |
EP3749372A1 (en) | 2020-12-16 |
UY38074A (es) | 2019-10-01 |
CL2020002052A1 (es) | 2021-01-04 |
BR112020012888A2 (pt) | 2020-12-08 |
MX2020008231A (es) | 2020-09-25 |
JP2021513536A (ja) | 2021-05-27 |
AU2019219201A1 (en) | 2020-07-23 |
AU2019219201B2 (en) | 2021-07-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB201811312D0 (en) | Compositions | |
GB2586745B (en) | Compositions | |
IL275713A (en) | IL-12 preparations targeting EDB | |
SG11202009259VA (en) | Compositions | |
SG11202104306XA (en) | Compositions | |
GB201809976D0 (en) | Novel formulations | |
GB201904338D0 (en) | Fluorouracil-containing formulations | |
GB201803923D0 (en) | Compositions | |
IL290356A (en) | Formulations for Resotide | |
CA193520S (en) | Blower | |
CA193523S (en) | Blower | |
IL284691A (en) | formulations | |
IL280829A (en) | dendrimer formulations | |
SG11202100161VA (en) | Anti-tumor composition | |
SG11202006789SA (en) | Flavour composition | |
PL3784026T3 (pl) | Dmuchawa | |
GB2570649B (en) | Compositions | |
GB201805676D0 (en) | Compositions | |
ZA202005658B (en) | Compositions | |
SG11202100654WA (en) | Flavour composition | |
ZA202104923B (en) | Soil stabilizing compositions | |
PT3768284T (pt) | Composições de flagelina entrecoccus para uso em terapia | |
SG11202011823SA (en) | Activator-nucleator formulations | |
GB201820233D0 (en) | Compositions | |
GB201816834D0 (en) | Compositions |